Source: Pharmaceutical Technology Europe
Issue 5,Volume 23
Outsourcing can have its benefits, but how often do we bother to measure the actual value of our outsourcing relationships?
Outsourcing can have its benefits, but how often do we bother to measure the actual value of our outsourcing relationships? Or the innovation they deliver? In Europe, at least, the answer is: not very often.
According to a study conducted by business consultancy services provider, Cognizant and the UK's Warwick Business School, about two-thirds of companies don't attempt to measure the value of innovation gained via outsourcing. The study encompassed 250 chief innovation officers (CIOs) and chief financial officers (CFOs) in Europe, and examined their attitudes about outsourcing for innovation.
Ironically, most CIOs and CFOs seem fully aware of the benefits that outsourcing brings. More than 60% of CIOs turn to outsourcing companies for innovation and 50% said they would be willing to pay more for an outsourced service that enables them to maintain innovation within their industry. Threequarters of respondents (70%) also believe that innovation achieved through outsourcing contributes to their organisation's financial performance. The study also notes that more is being spent on outsourcing now than at any other point during the past.
Speaking to PTE in an interview, Sanjiv Gossain, UK MD of Cognizant, explained the problem in greater detail. "While businesses are clearly turning to outsourcers to aid and deliver innovation within their organisations, many are missing a major opportunity to demonstrate the successful impact that this innovation is having within the organisation. This can only mean that money is being wasted by investment into innovation initiatives that are not delivering tangible results."
So why are so few companies actually measuring the value and innovation that they get from their investment?
One major hurdle lies in actually finding a method to successfully measure the value of outsourcing and the innovation it delivers. "The problem comes with defining innovation and educating businesses on how to successfully measure it to prove its impact on the company's bottom line," Gossain told PTE.
Ilan Oshri from Warwick Business School explained that the management of innovation is a key weakness in many businesses. However, Warwick Business School is now in the process of conducting qualitative research among C-level executives in more detail to put a figure on the value of innovation and further investigate the links between outsourcing and client organisations. The final findings will be available in a report later this year, available for download at www.valueofinnovation.com.
This isn't the first time that Cognizant and Warwick Business School have examined outsourcing issues. In 2009, they conducted a study about the benefits of outsourcing beyond the one-time cost saving. The results revealed that less than half of CIOs and CFOs try to calculate the impact of outsourcing on their business. If you missed out on this then you can catch up in the October and November 2009 issues of PTE, available on our website www.PharmTech.com.
"This new research into innovation, and the accompanying academic report due later this year, is a natural extension of our former study," said Gossain. "Modern outsourcing relationships now offer and deliver far more than just cost savings. Clients are now looking for more value from their outsourcing partnerships and innovation is a big part of this. This is a shift we are seeing across the industry."
Modern outsourcing relationships should help a business to innovate, and metrics should be established at the very beginning. It is also important to appraise any financial benefits that outsourcing for innovation offers.
"In order to drive repeatable innovation, companies need to establish a framework with their outsourcing partners to determine their objectives and formalise the innovation achieved," said Gossain. "Developing metrics will also help the C-level share the results and prove the worth of outsourcing-led innovation."
Pfizer sells Capsugel
Pfizer has sold Capsugel to Kohlberg Kravis Roberts & Co L.P for approximately $2.4 billion. Capsugel's headquarters will remain in New Jersey and any Pfizer staff dedicated to the business will be transferred to Capsugel.
Read more at: www.PharmTech.com/capsugel
Sanofi at the helm
Sanofi-aventis has, at last, gained full control over Genzyme, bringing the much talkedabout acquisition deal between the two companies to a close. The deal, which has been under negotiation since August 2010, will give sanofi an extended presence in the field of biotechnology and, in particular, rare diseases.
Read more at: www.PharmTech.com/fullcontrol
AstraZeneca settles taxes
AstraZeneca has paid $1.1 billion to settle a dispute with UK and US tax authorities concerning transferpricing arrangements for the company's US business. The amount, however, is lower than the company had anticipated. As a result, AstraZeneca will add $500 million to its first-quarter earnings for 2011.
Read more at: www.PharmTech.com/taxdispute
Global value of biosimilars
The global market for biosimilars is set to grow from $243 million in 2010 to $3.7 billion in 2015, according to Datamonitor. One of the key drivers for growth will be the loss of patent exclusivity for many branded products. More than 30 branded biologics with sales of $51 billion will lose patent exclusivity by 2015.
Read more at: www.PharmTech/biosimilars